drugset / Trial / NCT06119256
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EBV-TCR-T cells | Cell therapy | 300000 cells/kg | Other |
| Subject | EBV-TCR-T cells | Cell therapy | 500000 cells/kg | Other |
| Subject | EBV-TCR-T cells | Cell therapy | 1e+06 cells/kg | Other |